View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 7, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Co...

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m. PT. The presentation will be webcast live and may be accessed through Relay Therapeutics’ website under...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 4, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the ...

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin® Adds an additional commercial and strategic rare disease product to Eton’s portfolioGalzin is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired Galzin® (zinc acetate). “This acquisition furthers our...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 2, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 31, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 28, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 21, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

COP CONOCOPHILLIPS
OXY OCCIDENTAL PETROLEUM CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
VRSN VERISIGN INC.
TTSH TILE SHOP HOLDINGS INC.
RMAX RE/MAX HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
PBF PBF ENERGY INC. CLASS A
NMFC NEW MOUNTAIN FINANCE CORPORATION
MTDR MATADOR RESOURCES COMPANY
MMS MAXIMUS INC.
DLY LYONDELLBASELL INDUSTRIES NV
KVHI KVH INDUSTRIES INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
GLP GLOBAL PARTNERS LP
FPI FARMLAND PARTNERS REIT
FISI FINANCIAL INSTITUTIONS INC.
FFIC FLUSHING FINANCIAL CORP.
CNC CENTENE CORPORATION
CULP CULP INC.
FI FRANK'S INTERNATIONAL NV
NSC NORFOLK SOUTHERN CORPORATION
PETS PETMED EXPRESS INC.
PLSE PULSE BIOSCIENCES
SENS SENSEONICS HOLDINGS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
TDW TIDEWATER INC
DOW DOW INC.
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
BCYC BICYCLE THERAPEUTICS
OXLC OXFORD LANE CAPITAL CORP.
PHAT PHATHOM PHARMACEUTICALS
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
REYN REYNOLDS CONSUMER PRODUCTS INC.
PRLD PRELUDE THERAPEUTICS
DLHC DALEIGH HOLDINGS CORP
MASS 908 DEVICES
CTGO CONTANGO ORE INC.
UAN CVR PARTNERS LP
PFX PHENIXFIN CORP
RMBL RUMBLEON INC
XLO XILIO THERAPEUTICS INC
NVCT NUVECTIS PHARMA INC
BIGZ BLACKROCK INNOVATION AND GROWTH TST
BHRB BURKE & HERBERT BANK & TR/VA
ECBK ECB BANCORP INC.
DINO HF SINCLAIR CORP
TKO TKO GROUP HOLDINGS
GAM INC.
MIO GENERAL DE ALQUILER DE MAQUINARIA
SUNS PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
MDRR SUNRISE REALTY TRUST
SIRI MEDALIST DIVERSIFIED REIT INC.
EVM SIRIUS XM HLDGS INC NEW
TXO EATON VANCE INSD CALIF MUN BD FD
MORNINGSTAR PARTNERS
L.P.
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 20, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injec...

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection) Acquisition bolsters Eton’s commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions DEER PARK, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has completed its previously announced asset purchase of Increlex®...

 PRESS RELEASE

Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical T...

Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE® DEER PARK, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases announced the full readout and compelling results from the clinical trial evaluating PKU GOLIKE...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 14, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch